Early studies demonstrated that soluble IL-1 receptor (sIL-1R) and IL-1β receptor antagonists (IL-1RA) reversed the pro-survival effect of IL-1β on AML blasts in vitro [6]. The gene discussed is IL1B; the disease is acute myeloid leukemia.